To date, four CFTR modulator therapies have been approved and ∼90% CF patients with certain CFTR mutants are benefited with therapeutic outcomes (Ramsey et al., 2011; Rowe et al., 2017; Keating et al., 2018; Taylor-Cousar et al., 2018; Heijerman et al., 2019; Middleton et al., 2019). This evidence concerns the gene CFTR and cystic fibrosis.